Norway pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Patient Notes
Page 8 of 25 of this archive, newest first.
Page 8
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Diminishing returns, quantified
Escalation beyond the label is common in this market. Reporting that it happens is not the same as reporting that it works.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the placebo arms of the withdrawal trials actually tell us
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The intramuscular injection nobody intended
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Continued treatment against continued placebo: the comparison that settled it
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
What STEP 4 and SURMOUNT-4 actually established
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The Netherlands pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
A unit is not a dose, and it never was
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
What STEP 4 and SURMOUNT-4 actually established
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.